Transcode Therapeutics Inc (RNAZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $22.35M
Last updated: Nov 17, 2026 at 4:15 PM ET
Transcode Therapeutics Inc (RNAZ) Stock Chart
Transcode Therapeutics (RNAZ) has a latest price of $1.40 on Nov 17, 2026, 88.9% below its 52-week high of $12.60. Its price fell 84.8% over the past 12 months. The month-end price fell 100.0% over the 5 years through Oct 2026, a compound annual decline of 94.0%.
Price Chart
From Jul 2021 to Oct 2026, its highest month-end close was $2,248,292.06 in Aug 2021 and its lowest $1.63 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart RNAZ with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for RNAZ.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 56.4%, and over 6 months it fell 77.3%. The month-end price fell 100.0% over the 3 years through Oct 2026, a compound annual decline of 95.1%.
| Period | Change |
|---|---|
| 1 month | -17.6% |
| 3 months | -56.4% |
| 6 months | -77.3% |
| 12 months | -84.8% |
| 12 months, with dividends | -84.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -100.0% | -95.1% |
| 5 years | -100.0% | -94.0% |
Price by Year
Its best calendar year was 2022, when the price fell 73.5%, and its weakest was 2023, when it fell 98.8%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.63 | -76.1% |
| 2025 | $6.83 | -92.8% |
| 2024 | $94.40 | -98.5% |
| 2023 | $6,094.05 | -98.8% |
| 2022 | $497,730.45 | -73.5% |
Trading Range
The price is 14.7% below its 50-day average of $1.64 and 75.2% below its 200-day average of $5.64.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.40 | |
| 52-week high | $12.60 | -88.9% |
| 52-week low | $1.29 | +8.5% |
| 50-day average | $1.64 | -14.7% |
| 200-day average | $5.64 | -75.2% |
Price Risk
Over 3 years, its largest fall from a peak was 100.0%.
| Measure | Value |
|---|---|
| 1-year beta | 0.76 |
| Largest fall, 1 year | -89.3% |
| Largest fall, 3 years | -100.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About RNAZ
What is RNAZ's 1-year price change?
Transcode Therapeutics's price fell 84.8% over the past 12 months. With dividends included, the 12-month total return was -84.8%.
What is RNAZ's 5-year price change?
Transcode Therapeutics's month-end price fell 100.0% over the 5 years through Oct 2026, a compound annual decline of 94.0%. These figures leave out dividends.
What is RNAZ's 52-week high and low?
Transcode Therapeutics's 52-week high is $12.60 and its 52-week low is $1.29. Its latest price of $1.40 on Nov 17, 2026 is 88.9% below the high.
What is RNAZ's beta?
Transcode Therapeutics's 1-year beta against the S&P 500 is 0.76, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 89.3%.
Is the RNAZ chart free?
Yes. Advanced Charting for RNAZ is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
RNAZ pages: Overview, Charting, Earnings, Financials, Statistics, Competitors